Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2020.20052
Abstract: BACKGROUND Tisagenlecleucel was approved for the treatment of pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) based on the pivotal ELIANA trial. OBJECTIVE To comprehensively evaluate the total costs associated… read more here.
Keywords: young adult; tisagenlecleucel treatment; treatment; pediatric young ... See more keywords